JPS63192705A - External agent for skin - Google Patents
External agent for skinInfo
- Publication number
- JPS63192705A JPS63192705A JP62025440A JP2544087A JPS63192705A JP S63192705 A JPS63192705 A JP S63192705A JP 62025440 A JP62025440 A JP 62025440A JP 2544087 A JP2544087 A JP 2544087A JP S63192705 A JPS63192705 A JP S63192705A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- family
- extract
- plant
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 claims abstract description 27
- 241000219317 Amaranthaceae Species 0.000 claims abstract description 13
- 241000219357 Cactaceae Species 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 19
- 241000208465 Proteaceae Species 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 7
- 240000007643 Phytolacca americana Species 0.000 abstract description 6
- 235000009074 Phytolacca americana Nutrition 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract description 3
- 244000007853 Sarothamnus scoparius Species 0.000 abstract description 2
- 239000002932 luster Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 238000013329 compounding Methods 0.000 abstract 2
- 241000428811 Alternanthera Species 0.000 abstract 1
- 240000001913 Atriplex hortensis Species 0.000 abstract 1
- 244000298903 Basella rubra Species 0.000 abstract 1
- 235000009380 Basella rubra Nutrition 0.000 abstract 1
- 241000561734 Celosia cristata Species 0.000 abstract 1
- 244000301850 Cupressus sempervirens Species 0.000 abstract 1
- 244000224182 Gomphrena globosa Species 0.000 abstract 1
- 244000022198 Mirabilis jalapa Species 0.000 abstract 1
- 235000009053 Mirabilis jalapa Nutrition 0.000 abstract 1
- 241000219505 Phytolaccaceae Species 0.000 abstract 1
- 240000005860 Portulaca grandiflora Species 0.000 abstract 1
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 210000001520 comb Anatomy 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000006210 lotion Substances 0.000 description 12
- 238000000605 extraction Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000006096 absorbing agent Substances 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- 230000008326 skin blood flow Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- -1 ethanol or methanol Chemical compound 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 241000219050 Polygonaceae Species 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VUHMIPWBDMGTNL-MHCZMQLOSA-N 1,2-dimethoxy-4-[(e)-prop-1-enyl]benzene;1,2,4-trimethoxy-5-[(e)-prop-1-enyl]benzene Chemical compound COC1=CC=C(\C=C\C)C=C1OC.COC1=CC(OC)=C(\C=C\C)C=C1OC VUHMIPWBDMGTNL-MHCZMQLOSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 240000005528 Arctium lappa Species 0.000 description 2
- 235000003130 Arctium lappa Nutrition 0.000 description 2
- 235000008078 Arctium minus Nutrition 0.000 description 2
- 241000201841 Celosia Species 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000219304 Portulacaceae Species 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000016614 betalains Nutrition 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000008954 quail grass Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 1
- HXKWSTRRCHTUEC-UHFFFAOYSA-N 2,4-Dichlorophenoxyaceticacid Chemical compound OC(=O)C(Cl)OC1=CC=C(Cl)C=C1 HXKWSTRRCHTUEC-UHFFFAOYSA-N 0.000 description 1
- 241000219475 Bougainvillea Species 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000204357 Porites Species 0.000 description 1
- 241000219295 Portulaca Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、特定の植物抽出物を含む皮膚外用剤に関する
。本発明に係る皮膚外用剤は、皮膚になめらかさ及びし
っとり感を与え、つやとはりのあるきめのこまかな美し
い肌を作る作用を有し、更に皮膚血液循環を改善する効
果も併せもつ新規な皮膚外用剤である。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to an external skin preparation containing a specific plant extract. The skin external preparation according to the present invention is a novel skin preparation that has the effect of imparting smoothness and moisturization to the skin, creating smooth and beautiful skin with gloss and firmness, and also has the effect of improving skin blood circulation. It is an external preparation for the skin.
[従来の技術]
近年、天然界から医薬品、医薬部外品あるいは化粧品用
の有用成分を見いだそうとする試みが活発に行われてい
る。そのような観点から、種々の抽出物が報告されたり
、または抽出物中から有効成分を単離精製して報告され
る例も見受けられる。[Prior Art] In recent years, many attempts have been made to discover useful ingredients for pharmaceuticals, quasi-drugs, or cosmetics from the natural world. From this point of view, various extracts have been reported, and there have also been cases where active ingredients have been isolated and purified from the extracts.
[発明が解決しようとする問題点コ
本発明者らも、皮膚に対して特徴的な有効性あるいは有
用性を持つ天然成分を見出すべく、鋭意研究していたと
ころ、特定の植物群に肌荒れ改善、皮膚血液循環改善な
どの効果あることを発見し、本発明を完成するに至った
。[Problems to be Solved by the Invention] The inventors of the present invention have been conducting intensive research to find natural ingredients that have characteristic efficacy or usefulness for the skin. They discovered that it has effects such as improving skin blood circulation, and completed the present invention.
[問題点を解決するための手段]
すなわち本発明は、アカザ科植物、ヒユ科植物、オシロ
イバナ科植物、ヤマゴボウ科植物、ツルナ科植物、スベ
リヒユ科植物、ツルムラサキ科植物またはサボテン科植
物の抽出物から選ばれる一種又は二種以上の抽出物を含
有することを特徴とする皮膚外用剤である。[Means for Solving the Problems] That is, the present invention provides an extract from a Chenopodiaceae plant, an Amaranthaceae plant, a Psyllidaceae plant, a Polygonaceae plant, an Ornataceae plant, a Portulacaceae plant, a Trifoliaceae plant, or a Cactaceae plant. This is an external skin preparation characterized by containing one or more selected extracts.
これら植物は、ベタレイン類を多く含有する植物として
知られている。本発明皮膚外用剤の効果の作用機序は明
らかではないが、ベタレイン類がなんらかの関与をなし
ている可能性もある。These plants are known to contain a large amount of betalains. Although the mechanism of action of the external skin preparation of the present invention is not clear, it is possible that betalains may be involved in some way.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
本発明に用いる植物抽出物はアカザ科植物、ヒユ科植物
、オシロイバナ科植物、ヤマゴボウ科植物、ツルナ科植
物、スベリヒユ科植物、ツルムラサキ科植物またはサボ
テン科植物から抽出される抽出物である。アカザ科植物
としてはハマアカザ、ヒユ科植物としてはホウキギ、ツ
ルノケイトウ、スギモリケイトウ、ケイトウ、センニチ
ュウ、オシロイバナ科植物としてはブーゲンビリア、オ
シロイバナ、ヤマゴボウ科植物としてはヤマゴボウ、ツ
ルナ科植物、スベリヒユ科植物としてはマツバボタン、
ツルムラサキ科植物としてはツルムラサキなどが例示さ
れる。The plant extract used in the present invention is an extract extracted from a plant of the family Chenopodiaceae, a plant of the family Amaranthaceae, a plant of the family Psyllidaceae, a plant of the family Proteaceae, a plant of the family Ornataceae, a plant of the family Portulaceae, a plant of the family Arunaceae, or a plant of the family Cactaceae. The Chenopodiaceae plants include the Amaranthaceae, the Amaranthaceae plants include the Broom tree, the Celosiaceae, the Celosia nigra, and the Celosia nigra, the Porcineaceae plants include the bougainvillea, the Polygonaceae family, the Polygonaceae family plants include the Porites, the Amaranthaceae plants, and the Purslane family plants include the Matsuba button,
Examples of plants belonging to the family Surinamedae include Tsurumarasaki and the like.
抽出部位は任意であるが、主として実、葉、茎等の地上
部である。これらの部位の植物細胞を培養して、培養細
胞中から抽出物を得てもよい。より品質の安定した抽出
物を工業的に製造することができる。Extraction parts are arbitrary, but mainly above-ground parts such as fruits, leaves, and stems. Plant cells from these sites may be cultured to obtain an extract from the cultured cells. Extracts with more stable quality can be produced industrially.
抽出方法はとくに限定されないが、溶媒、たとえば水、
エタノール或いはメタノール等のアルコール、プロピレ
ングリコール、1.3−ブチレングリコール等の多価ア
ルコールを用いて室温又は冷所で攪拌して抽出するのが
一般的である。抽出物は、そのまま用いてもよいし濃縮
して用いてもよいし、あるいは乾燥固形物として用いて
もよい(以下、抽出物の量は乾燥固型分重量で記す)。The extraction method is not particularly limited, but a solvent such as water,
Extraction is generally carried out using an alcohol such as ethanol or methanol, or a polyhydric alcohol such as propylene glycol or 1,3-butylene glycol, with stirring at room temperature or in a cold place. The extract may be used as it is, or may be used after being concentrated, or may be used as a dry solid (hereinafter, the amount of extract is expressed in terms of dry solid weight).
本発明においては上記植物の抽出物の任意の一種又は二
種以上を皮膚外用剤基剤中に配合する。In the present invention, one or more of the above-mentioned plant extracts are blended into the skin external preparation base.
配合量は皮膚外用剤全量中の0.0001〜30重量%
、好ましくは0.005〜20宙量%である。0.00
01重量%未満では本発明の効果が得られないので好ま
しくなく、逆に30重量%を超えると皮膚外用剤として
の製剤が困難であり、また皮膚、着衣等への着色が著し
いので好ましくない。The blending amount is 0.0001 to 30% by weight of the total amount of the skin external preparation.
, preferably 0.005 to 20% by weight. 0.00
If it is less than 0.01% by weight, the effect of the present invention cannot be obtained, so it is not preferable. On the other hand, if it exceeds 30% by weight, it is difficult to formulate it as an external preparation for the skin, and it is also undesirable because it causes significant coloring on the skin, clothing, etc.
本発明の皮膚外用剤には、上記必須成分に加えて必要に
応じ、また皮膚外用剤のタイプに応じてさらに、紫外線
吸収剤、酸化防止剤、油分、水、界面活性剤、保湿剤、
低級アルコール、増粘剤、香料、キレート剤、色素、防
腐防黴剤などの皮膚外用剤に一般い用いられる成分を配
合することができる。In addition to the above-mentioned essential ingredients, the external skin preparation of the present invention may further contain ultraviolet absorbers, antioxidants, oils, water, surfactants, humectants, as necessary and depending on the type of external skin preparation.
Ingredients commonly used in external skin preparations, such as lower alcohols, thickeners, fragrances, chelating agents, pigments, and antiseptic and antifungal agents, can be blended.
とくに紫外線吸収剤または酸化防止剤については、これ
らの中から任意の一種又は二種以上を配合することによ
り、植物抽出物の安定化が図られより優れた皮膚外用剤
が得られる。In particular, with regard to ultraviolet absorbers or antioxidants, by incorporating one or more of them, the plant extract can be stabilized and a more excellent skin preparation can be obtained.
紫外線吸収剤としては、例えば2−ヒドロキシ4−メト
キシベンゾフェノン5−スルホン酸ナトリウム(商品名
;ASL−243、以下同じ)、バラジメチルアミノ安
息香酸メチル(商品名;エスカロール506、以下同e
) 、ウロカニン酸、2−ヒドロキシ−4−メトキシベ
ンゾフェノン、2゜2゛−ジヒドロキシ4.4”−ジメ
トキシベンゾフェノン等の皮膚外用剤に使用可能な紫外
線吸収剤をあげることができる。かかる紫外線吸収剤の
使用量には特に限定はないが、好ましくはo、ooi〜
5重量%、更に好ましくは0.1〜2重量%含ませるこ
とができる。Examples of ultraviolet absorbers include sodium 2-hydroxy 4-methoxybenzophenone 5-sulfonate (trade name: ASL-243, the same hereinafter), methyl valadimethylaminobenzoate (trade name: Escarol 506, the same hereinafter).
), urocanic acid, 2-hydroxy-4-methoxybenzophenone, 2゜2゛-dihydroxy-4.4''-dimethoxybenzophenone, and other ultraviolet absorbers that can be used in external skin preparations. There is no particular limitation on the amount used, but preferably o, ooi ~
It can be contained in an amount of 5% by weight, more preferably 0.1 to 2% by weight.
酸化防止剤としては、例えばビタミンC、ビタミンE、
タンニン酸、没食子酸、ブチルヒドロキシアニソール、
エリソルビン酸等の皮膚外用剤に使用可能な酸化防止剤
を挙げることができる。これらの酸化防止剤の配合量に
もとくに限定はないが、好ましくは0.001〜5重量
%、更に好ましくは0.1〜2重量%配合することがで
きる。Examples of antioxidants include vitamin C, vitamin E,
Tannic acid, gallic acid, butyl hydroxyanisole,
Examples include antioxidants that can be used in external skin preparations such as erythorbic acid. There is no particular limitation on the amount of these antioxidants, but it is preferably 0.001 to 5% by weight, more preferably 0.1 to 2% by weight.
また本発明の剤型は任意であり、溶液系、油分系、乳化
系、粉末分散系、水−油二層系、水−油一粉末三層系の
ような剤型でも構わない。Further, the dosage form of the present invention is arbitrary, and may be a solution type, an oil type, an emulsion type, a powder dispersion type, a water-oil two-layer system, or a water-oil one-powder three-layer system.
更に本発明の皮膚外用剤の用途も任意であり、化粧水、
乳液、クリーム、バック等のフエーシャル化粧品やヘア
トニック、ヘアリキッド等の頭髪化粧品はもちろん、フ
ァンデーション、口紅、アイシャドー等メーキャップ化
粧品やボディ化粧品に用いることができる。Furthermore, the use of the skin external preparation of the present invention is arbitrary, and it can be used as a lotion,
It can be used not only in facial cosmetics such as emulsions, creams, and bags, and hair cosmetics such as hair tonics and hair liquids, but also in makeup cosmetics and body cosmetics such as foundations, lipsticks, and eye shadows.
[実施例コ
以下、実施例に従って本発明を更に詳細に説明するが、
本発明の技術的範囲をこれらに限定するものではないこ
とはいうまでもない。配合量は重量%を示す。[Example] Hereinafter, the present invention will be explained in more detail according to Examples.
It goes without saying that the technical scope of the present invention is not limited to these. The blending amount indicates weight %.
抽出例1
ヨウシュヤマゴボウ培養細胞を、Linsmaier
−Scoog培地を基本としてシam3%、2,4−ジ
クロロフェノキシ酢酸5X10Mを含む液体培地で9日
間培養した。Extraction Example 1 Cultured pokeweed cells were cultured using Linsmaier
- Cultivation was carried out for 9 days in a liquid medium based on Scoog's medium containing 3% SAM and 5×10M of 2,4-dichlorophenoxyacetic acid.
得られたヨウシュヤマゴボウ培養細胞3.9Kg(生重
量)に39fのメタノールを加え、ホモジナイズした後
、残さを再び391のメタノールに浸漬けした。1晩攪
拌した後、上清を先の上清とあわせ、減圧でメタノール
を留去して、抽出物116gを得た。After adding 39 f methanol to 3.9 kg (fresh weight) of the obtained pokeweed cultured cells and homogenizing them, the residue was immersed in 391 methanol again. After stirring overnight, the supernatant was combined with the previous supernatant, and methanol was distilled off under reduced pressure to obtain 116 g of an extract.
抽出例2
乾燥、粉砕したマツバボタンの地上部5Kgに70%エ
タノール501を加え攪拌した後、残さを再び501の
70%エタノールに浸漬した。1晩攪拌した後、上清を
先の上清とあわせ、減圧でエタノールを留去して、抽出
物1.2Kgを得た。Extraction Example 2 After adding 70% ethanol 501 to 5 kg of the above-ground parts of dried and crushed Portulaca elegans and stirring, the residue was immersed again in 70% ethanol 501. After stirring overnight, the supernatant was combined with the previous supernatant, and ethanol was distilled off under reduced pressure to obtain 1.2 kg of extract.
抽出例3
乾燥、粉砕したツルムラサキの地上部3Kgに70%1
,3−ブチレングリコール水溶液30j?を加え攪拌し
た後、残さを再び30I!の70%エタノールに浸漬し
た。1晩攪拌した後、上清を先の上清とあわせ、減圧で
1,3−ブチレングリコールを留去して、抽出物582
gを得た。Extraction example 3 70% 1 to 3 kg of the above ground part of dried and crushed Tsurumurasaki
, 3-butylene glycol aqueous solution 30j? After adding and stirring, add 30I of the residue again! 70% ethanol. After stirring overnight, the supernatant was combined with the previous supernatant, and 1,3-butylene glycol was distilled off under reduced pressure to obtain extract 582.
I got g.
実施例1
■ グリセリン 5.0■ ク
エン酸 0.03■ クエ
ン酸ソーダ 0.05■ アラン
トイン 0.1■ エタノール
(95%) 10.0■ POE
(*−1) (15モル)オレイルエーテル
1.0
■ 抽出例1の抽出物 0.5■
ASL−24S O,3■
香料 0.1[相]
防腐剤 0.10 色素
適量@ 精製水
残余*−1;ポリオキシエ
チレン;以下同じ。Example 1 ■ Glycerin 5.0 ■ Citric acid 0.03 ■ Sodium citrate 0.05 ■ Allantoin 0.1 ■ Ethanol (95%) 10.0 ■ POE
(*-1) (15 mol) Oleyl ether
1.0 ■ Extract of Extraction Example 1 0.5 ■
ASL-24S O, 3■
Fragrance 0.1 [phase]
Preservative 0.10 Pigment Appropriate amount @ Purified water
Remaining *-1; polyoxyethylene; the same applies hereinafter.
(製法)
上記成分■、■、■及び[相]を室温にて混合熔解し、
同じく室温にて混合熔解した成分■、■、■、■、■、
■、■及び@中へ攪拌添加して化粧水を得た。(Production method) Mix and melt the above components ■, ■, ■ and [phase] at room temperature,
Similarly, the components mixed and melted at room temperature■,■,■,■,■,
A lotion was obtained by stirring and adding to the contents of ①, ② and @.
一方、上記実施例1の配合から■ヨウシュヤマゴボウ抽
出液を除いた以外は全て実施例1と同様にして比較例1
の化粧水を得た。On the other hand, Comparative Example 1 was carried out in the same manner as in Example 1, except that ■ Yamato burdock extract was removed from the formulation of Example 1.
I got lotion.
(評価試験)
実施例1および比較例1の化粧水について、女性パネル
20名により使用テストを行った。すなわち実施例1お
よび比較例1の化粧水容0.5−を左右前腕部内側に1
日2回、3力月間連続通用し、その効果について調査し
た。(Evaluation Test) A usage test was conducted on the lotions of Example 1 and Comparative Example 1 by a panel of 20 women. That is, 1 volume of the lotion of Example 1 and Comparative Example 1 was applied to the inside of the left and right forearms.
The product was used twice a day for three consecutive months, and its effects were investigated.
fl) 肌のなめらかさ及びしっとり感についてはパ
ネル自身に、有効、やや有効、無効の3段階で評価して
もらった。fl) Regarding the smoothness and moisturizing of the skin, the panel members themselves were asked to rate the results in three stages: effective, somewhat effective, and ineffective.
結果は第1表に示す通りであった。The results were as shown in Table 1.
(2)肌のつや、はりについてはパネルの皮膚(実施例
1通用部)の弾性率を比較例のそれと同様に測定した。(2) Regarding skin gloss and firmness, the elastic modulus of the skin of the panel (example 1 common area) was measured in the same manner as that of the comparative example.
結果は第2表に示す通りであった。The results were as shown in Table 2.
(3)通用部位の皮膚流血量について、レーザードツプ
ラー血流計を用いてパネルの実施例1の化粧水通用部と
比較例1の化粧水適用部を測定し、比較した。(3) The amount of skin blood flow in the application area was measured using a laser Doppler blood flow meter in the lotion application area of Example 1 and the lotion application area of Comparative Example 1 of the panel, and compared.
結果は第3表に示す通りであった。The results were as shown in Table 3.
(4)動物実験
マウス(ICR−JCL系雄、体重21〜24g)の背
部の毛を刈り、実施例1および比較例1の化粧水を0.
2d/日で2力月間連続して背部皮膚に塗布した。塗布
終了日から24時間後に背部皮膚を採取し、その中のヒ
アルロン酸量を測定した(ムコ多糖実験法(1)、19
72.31頁〜125頁参照)。(4) Animal experiment The hair on the back of a mouse (ICR-JCL male, weight 21-24 g) was shaved, and the lotions of Example 1 and Comparative Example 1 were applied at 0.00%.
It was applied to the back skin continuously for 2 months at 2 days/day. The back skin was collected 24 hours after the application was completed, and the amount of hyaluronic acid therein was measured (Mucopolysaccharide Experimental Method (1), 19
72. See pages 31 to 125).
結果は第4表に示す通りであった。The results were as shown in Table 4.
(以下余白)
第1表
肌のなめらかさ
有 効 15/20 1/20やや有
効 5/20 2/20
無 効 0/20 1?/20肌のし
っとり感
有 効 16/20 0/20やや有
効 4/20 3/20
以上の結果から実施例1を通用した部位の皮膚状態は明
らかに改善されていることを確認した。(Left below) 1st surface Skin smoothness Effective 15/20 1/20 Slightly effective 5/20 2/20 Ineffective 0/20 1? /20 Skin moist feeling Effective 16/20 0/20 Slightly effective 4/20 3/20 From the above results, it was confirmed that the skin condition of the area where Example 1 was applied was clearly improved.
なお皮膚状態が悪化した例はなかった。There were no cases where the skin condition deteriorated.
(以下余白)
第2表
パネル 弾性率 T (dyne 01m2XI
O8)平均値 2.17 2.38 2
.37以上の結果から明らかなように、実施例1の化粧
水を通用した部位の皮膚弾性率は低下しており皮膚のは
りが増加していることが確認された。(Margins below) Table 2 Panel Elastic modulus T (dyne 01m2XI
O8) Average value 2.17 2.38 2
.. 37 As is clear from the above results, it was confirmed that the skin elastic modulus of the area where the lotion of Example 1 was applied decreased and the firmness of the skin increased.
第3表
平均±SD 112.5±9.1 98.9
±4.3上記の結果から明らかなように、実施例1の化
粧水通用部位の皮膚血流量が比較系1の化粧水通用部位
に比較して増加していることが確認された。Table 3 Mean ± SD 112.5 ± 9.1 98.9
±4.3 As is clear from the above results, it was confirmed that the skin blood flow in the area where the lotion was applied in Example 1 was increased compared to the area where the lotion was applied in Comparative System 1.
この原因についてはヨウシュヤマゴボウ抽出物による血
管拡張作用が考えられる。なお、実際にウサギ摘出動脈
に対してヨウシュヤマゴボウ抽出物は拡張作用を示した
。The cause of this is thought to be the vasodilatory effect of the pokeweed extract. Incidentally, a pokeweed extract actually showed a dilating effect on isolated rabbit arteries.
第4表 マウス背部皮膚のヒアルロン酸量以上の結果か
ら明らかなように、実施例1の化粧水は対照(無処理)
および比較例1に対“し危険率1%以下で有意(を検定
)に皮膚ヒアルロン酸量を増加させることが判明した。Table 4 As is clear from the results of the amount of hyaluronic acid on the back skin of mice, the lotion of Example 1 was used as a control (untreated)
It was also found that compared to Comparative Example 1, the amount of hyaluronic acid in the skin was significantly increased (tested) with a risk rate of 1% or less.
第1表〜第3表の結果と併せ考察すると、肌のなめらか
さ、しっとり感、皮膚弾性率に関して皮膚に好ましい効
果が明らかになった1つの原因として皮膚ヒアルロン酸
量の増加が考えられる。When considered together with the results in Tables 1 to 3, an increase in the amount of hyaluronic acid in the skin is considered to be one of the reasons why the favorable effects on the skin regarding skin smoothness, moist feeling, and skin elasticity were revealed.
ヒアルロン酸量の増加について、その機構は明確ではな
いが、ヨウシュヤマゴボウの抽出物がヒアルロン酸分解
酵素に対し抑制的に作用することを本発明者らは確認し
ており、このことが1つの要素となっている可能性が推
察される。Although the mechanism behind the increase in the amount of hyaluronic acid is not clear, the present inventors have confirmed that extract of Yama burdock has an inhibitory effect on hyaluronan degrading enzymes, and this is one of the reasons why It is inferred that this may be a factor.
次に、本発明の係る植物抽出物の安定性について、実験
例を示す。Next, an experimental example will be shown regarding the stability of the plant extract according to the present invention.
試料に50℃の環境下でキセノンランプにより光を照射
しく 461X 10’ J / m) 、5時間及び
30時時間量大吸収波長(λ max)における吸光度
を測定した。The sample was irradiated with light using a xenon lamp in an environment of 50° C. (461×10′ J/m), and the absorbance at the large absorption wavelength (λ max) was measured for 5 hours and 30 hours.
結果は第5表に示した通りである。The results are shown in Table 5.
(以下余白)
第5表
*−3;ポリオキシエチレン(60モル)硬化ヒマシ油
(以下余白)
以上のようにヨウシュヤマゴボウ抽出液単独あるいは界
面活性剤を添加した試料は退色が著しかったが、紫外線
吸収剤及び/または酸化防止剤を添加することにより、
光による退色を極めて良好に改善できた。(The following is the margin) Table 5*-3: Polyoxyethylene (60 mol) Hydrogenated castor oil (The following is the margin) As mentioned above, the color fading was significant for the pokeweed extract alone or with the addition of a surfactant. By adding ultraviolet absorbers and/or antioxidants,
The fading caused by light could be improved very well.
実施例2
■ グリセリン 5.0■ ポ
リエチレングリコール 2.0(分子量4
00)
■ グリチルリチン酸 0.1モノ
アンモニウム塩
■ アラントイン 0.1■
抽出物例2の抽出物 1.0■ セタ
ノール 4.0■ スクワラ
ン 5.0■ ステアリン酸
1.0■ ミツロウ
1.0[相] ワセリン
1.00 POE(25モル
)セチルエーテル 2.00 グリセリルモノステ
アレート 1.50 防腐剤
0.10 香料
0.15■ A S L −24S
O,3[相] 没食
子酸 1.00 精製水
残余(製法)
成分■〜[相]を混合溶解し、同じく混合溶解した成分
■、■、■、■、■の中へ攪拌混合して乳化した。ホモ
ジナイジーにより乳化粒子を整え、その後熱交換器にて
室温まで冷却してW10型クリームを得た。Example 2 ■ Glycerin 5.0 ■ Polyethylene glycol 2.0 (molecular weight 4
00) ■ Glycyrrhizic acid 0.1 monoammonium salt ■ Allantoin 0.1 ■
Extract of Extract Example 2 1.0 ■ Setanol 4.0 ■ Squalane 5.0 ■ Stearic acid 1.0 ■ Beeswax
1.0 [phase] Vaseline
1.00 POE (25 mol) Cetyl ether 2.00 Glyceryl monostearate 1.50 Preservative
0.10 fragrance
0.15■ASL-24S
O,3 [phase] Gallic acid 1.00 Purified water
Residue (manufacturing method) Ingredients (1) to [phase] were mixed and dissolved, and stirred and mixed into the similarly mixed and dissolved components (2), (2), (2), (2), and (3) to emulsify. Emulsified particles were prepared by homogenization, and then cooled to room temperature using a heat exchanger to obtain W10 type cream.
実施例3
■ ポリビニルアルコール 10.O■
ポリエチレングリコール 0.4(分子
量400)
■ グリセリン 3.0■ エタ
ノール(95%)8.0
0 抽出例1の抽出物 0.5■ A
S L −24S O,5■
防腐剤 0.1■ 香
料 0.1■ 精製
水 残余(製法)
室温で成分■〜■を混合溶解し、これを成分■、■、■
および■を混合熔解した中に攪拌添加した後、室温まで
冷却してパックを得た。Example 3 ■ Polyvinyl alcohol 10. O■
Polyethylene glycol 0.4 (molecular weight 400) ■ Glycerin 3.0 ■ Ethanol (95%) 8.0 0 Extract of Extraction Example 1 0.5 ■ A
SL-24S O, 5■
Preservative 0.1■ Fragrance 0.1■ Purified water Remaining (manufacturing method) Mix and dissolve ingredients ■~■ at room temperature, and add this to ingredients ■, ■, ■
and (2) were added to the mixed and melted mixture with stirring, and the mixture was cooled to room temperature to obtain a pack.
実施例4
■ スクワラン 5.0■
ワセリン 2.0■ ミ
ツロウ 0.5■ ソル
ビタンセスキオレイン酸エステル 0.8■ POE(
20モル)オレイルエーテル 1.2■ プロピレン
グリコール 5.0■ 抽出例3の抽出
物 0.5■ エスカロール5o60
.2
■ タンニン酸 0.3[相
] エタノール 10.00
香料 通量@ 防腐剤
通量0 精製水
残余(製法)
上記成分■、■、■、■、■、■及び@を70℃にて攪
拌溶解して油相とした。一方、成分■、■、■及び■を
成分0中に溶解して水相とし70℃に保った。直前に成
分■を水相中へ混入した後、さらに油相を混合して乳液
を得た。Example 4 ■ Squalane 5.0 ■
Vaseline 2.0 ■ Beeswax 0.5 ■ Sorbitan sesquioleate 0.8 ■ POE (
20 mol) Oleyl ether 1.2■ Propylene glycol 5.0■ Extract of Extraction Example 3 0.5■ Escarol 5o60
.. 2 ■ Tannic acid 0.3 [phase] Ethanol 10.00
Fragrance amount @ Preservative amount 0 Purified water
Residue (manufacturing method) The above components (1), (2), (2), (2), (2), (2) and @ were stirred and dissolved at 70°C to form an oil phase. On the other hand, components (1), (2), (2) and (2) were dissolved in component 0 to form an aqueous phase and maintained at 70°C. Immediately before, component (1) was mixed into the aqueous phase, and then the oil phase was further mixed to obtain an emulsion.
実施例5
■ ヒマシ油 20.0■
セチルアルコール 20.O■ ミ
ツロウ 5.0■ キャ
ンデリラロウ 30.O■ 抽出例
1の抽出物 0.5■ 、A S
L −2430,5
■ スクワラン 13.0■
カルナバロウ 5.0■ 顔
料 5.0[相] 香
料 i!I量(製法)
成分■〜[相]を80℃にて混合溶解し、型に流し込ん
で室温まで放冷した後、型から取り出して棒状口紅を得
た。Example 5 ■ Castor oil 20.0 ■
Cetyl alcohol 20. O■ Beeswax 5.0■ Candelilla wax 30. O■ Extract of Extraction Example 1 0.5■, A S
L -2430,5 ■ Squalane 13.0■
Carnauba wax 5.0 ■ Pigment 5.0 [phase] Fragrance i! Amount I (manufacturing method) Ingredients (1) to [phase] were mixed and dissolved at 80°C, poured into a mold, allowed to cool to room temperature, and then taken out from the mold to obtain a lipstick stick.
本発明の皮膚外用剤は、皮膚に対して、なめらかさおよ
びしっとり感を与え、また皮膚血流量を増大させて皮膚
を賦活し、皮膚にはり、つやを与え、肌荒れの防止及び
改善に極めて有用な皮膚外用剤である。The external skin preparation of the present invention gives a smooth and moist feeling to the skin, increases skin blood flow, revitalizes the skin, gives firmness and luster to the skin, and is extremely useful for preventing and improving skin roughness. It is a topical skin preparation.
Claims (1)
、ヤマゴボウ科植物、ツルナ科植物、スベリヒユ科植物
、ツルムラサキ科植物またはサボテン科植物の抽出物か
ら選ばれる一種又は二種以上の抽出物を含有することを
特徴とする皮膚外用剤。(1) Contains one or more extracts selected from the extracts of Chenopodiaceae, Amaranthaceae, Alocataceae, Proteaceae, Trunaceae, Portulaceae, Trifoliaceae, or Cactaceae. A skin external preparation characterized by:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62025440A JPS63192705A (en) | 1987-02-05 | 1987-02-05 | External agent for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62025440A JPS63192705A (en) | 1987-02-05 | 1987-02-05 | External agent for skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63192705A true JPS63192705A (en) | 1988-08-10 |
Family
ID=12166060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62025440A Pending JPS63192705A (en) | 1987-02-05 | 1987-02-05 | External agent for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63192705A (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0899889A (en) * | 1994-08-02 | 1996-04-16 | Taisho Pharmaceut Co Ltd | Therapeutic agent for atopic dermatitis |
WO1997034579A1 (en) * | 1996-03-21 | 1997-09-25 | Pierre Fabre Dermo-Cosmetique | Amaranth seed extract and skin cosmetic composition containing same |
JP2000143488A (en) * | 1998-11-16 | 2000-05-23 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing humectant plant extract |
US6210738B1 (en) | 1999-04-23 | 2001-04-03 | E Excel Internatioanal Inc. | Freeze-dried ginseng berry tea |
JP2001106619A (en) * | 1999-10-05 | 2001-04-17 | Ichimaru Pharcos Co Ltd | Cosmetic composition |
US6238672B1 (en) | 1999-04-23 | 2001-05-29 | E. Excel International Inc. | Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice |
KR20020012303A (en) * | 2002-01-28 | 2002-02-15 | 박동인 | a salt grass massage pack |
JP2002205951A (en) * | 2001-01-12 | 2002-07-23 | Itec:Kk | Skin medicinal composition or bathing agent |
KR100362498B1 (en) * | 2000-10-05 | 2002-11-29 | 애경산업(주) | Hamcho containinig cosmetics |
US6524626B2 (en) | 1999-04-23 | 2003-02-25 | E Excel International, Inc. | Ginseng berry topical products |
US6576286B1 (en) | 1999-04-23 | 2003-06-10 | E Excel International | Cactus fruit drinks and food products |
JP2005504088A (en) * | 2001-09-24 | 2005-02-10 | ラボラトイレス クラリンス | Cosmetic composition for caring for male skin and hair |
FR2868311A1 (en) * | 2004-04-02 | 2005-10-07 | Silab Sa | Preparation of active ingredient with slimming cosmetic activity through stimulation of lipolytic activity of adipocytes, comprises solubilization of powder of Celosia cristata and Prunella vulgaris in the presence of carbohydrase |
JP2006151834A (en) | 2004-11-25 | 2006-06-15 | Nof Corp | Skin cosmetic |
JP2006248932A (en) * | 2005-03-09 | 2006-09-21 | Kanebo Ltd | Humectant and cosmetic containing the same |
JP2013155140A (en) * | 2012-01-30 | 2013-08-15 | Toyo Shinyaku Co Ltd | Composition and cosmetic |
WO2015140679A1 (en) | 2014-03-17 | 2015-09-24 | Sederma | Cosmetic use of an extract of mirabilis jalapa |
WO2015162051A1 (en) * | 2014-04-23 | 2015-10-29 | Société De Recherche Cosmétique S.À.R.L. | Cosmetic compositions for topical application comprising bougainvillea plant cells |
EP3721944A1 (en) | 2013-09-22 | 2020-10-14 | Cutech S.R.L. | Extracts of halimione portulacoides and their application |
-
1987
- 1987-02-05 JP JP62025440A patent/JPS63192705A/en active Pending
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0899889A (en) * | 1994-08-02 | 1996-04-16 | Taisho Pharmaceut Co Ltd | Therapeutic agent for atopic dermatitis |
WO1997034579A1 (en) * | 1996-03-21 | 1997-09-25 | Pierre Fabre Dermo-Cosmetique | Amaranth seed extract and skin cosmetic composition containing same |
FR2746303A1 (en) * | 1996-03-21 | 1997-09-26 | Fabre Pierre Dermo Cosmetique | AMARANTE SEED EXTRACT AND DERMO-COSMETIC COMPOSITION COMPRISING THE SAME |
JP2000143488A (en) * | 1998-11-16 | 2000-05-23 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing humectant plant extract |
US6524626B2 (en) | 1999-04-23 | 2003-02-25 | E Excel International, Inc. | Ginseng berry topical products |
US6210738B1 (en) | 1999-04-23 | 2001-04-03 | E Excel Internatioanal Inc. | Freeze-dried ginseng berry tea |
US6238672B1 (en) | 1999-04-23 | 2001-05-29 | E. Excel International Inc. | Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice |
US6576286B1 (en) | 1999-04-23 | 2003-06-10 | E Excel International | Cactus fruit drinks and food products |
JP2001106619A (en) * | 1999-10-05 | 2001-04-17 | Ichimaru Pharcos Co Ltd | Cosmetic composition |
KR100362498B1 (en) * | 2000-10-05 | 2002-11-29 | 애경산업(주) | Hamcho containinig cosmetics |
JP2002205951A (en) * | 2001-01-12 | 2002-07-23 | Itec:Kk | Skin medicinal composition or bathing agent |
JP2005504088A (en) * | 2001-09-24 | 2005-02-10 | ラボラトイレス クラリンス | Cosmetic composition for caring for male skin and hair |
KR20020012303A (en) * | 2002-01-28 | 2002-02-15 | 박동인 | a salt grass massage pack |
FR2868311A1 (en) * | 2004-04-02 | 2005-10-07 | Silab Sa | Preparation of active ingredient with slimming cosmetic activity through stimulation of lipolytic activity of adipocytes, comprises solubilization of powder of Celosia cristata and Prunella vulgaris in the presence of carbohydrase |
JP2006151834A (en) | 2004-11-25 | 2006-06-15 | Nof Corp | Skin cosmetic |
JP2006248932A (en) * | 2005-03-09 | 2006-09-21 | Kanebo Ltd | Humectant and cosmetic containing the same |
JP2013155140A (en) * | 2012-01-30 | 2013-08-15 | Toyo Shinyaku Co Ltd | Composition and cosmetic |
EP3721944A1 (en) | 2013-09-22 | 2020-10-14 | Cutech S.R.L. | Extracts of halimione portulacoides and their application |
WO2015140679A1 (en) | 2014-03-17 | 2015-09-24 | Sederma | Cosmetic use of an extract of mirabilis jalapa |
WO2015162051A1 (en) * | 2014-04-23 | 2015-10-29 | Société De Recherche Cosmétique S.À.R.L. | Cosmetic compositions for topical application comprising bougainvillea plant cells |
FR3020272A1 (en) * | 2014-04-23 | 2015-10-30 | Rech Cosmetique S A R L Soc D | COSMETIC COMPOSITIONS WITH TOPICAL APPLICATION COMPRISING VEGETABLE CELLS OF BOUGAINVILLIER |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69916197T2 (en) | Composition that has a cooling effect | |
JPS63192705A (en) | External agent for skin | |
JPH01265017A (en) | Light protective composition containing sorbohydroxamic acid and anti-inflammory drug | |
JPS6248611A (en) | External preparation for skin | |
JPS5883648A (en) | Lanolin acid copper and local composition | |
US5637304A (en) | Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use | |
JPH10203955A (en) | Antimicrobial low-irritating cosmetic | |
JP2001081008A (en) | Skin preparation for external use keeping and improving the skin from chapping | |
JPH09221410A (en) | Aging preventing skin ointment | |
JPH0532556A (en) | Skin agent for external use | |
JPH10139601A (en) | Antimicrobial and antimicrobial cosmetic material containing the same | |
JPH0840824A (en) | Cosmetic | |
JP3319870B2 (en) | Skin external composition and bath agent | |
JP2001278783A (en) | Collagen production promoter | |
JP2000159653A (en) | Preparation for external use for skin | |
JPS63215611A (en) | Cosmetic | |
JPH11209223A (en) | Humectant and preparation for external use for skin | |
JP3270219B2 (en) | External preparation for skin | |
JPH11302147A (en) | Cosmetic | |
JP4124318B2 (en) | Antioxidants and external preparations for skin | |
JPH10203954A (en) | Antimicrobial low-irritating cosmetic | |
JP5004045B2 (en) | Antibacterial agent and antibacterial composition | |
JPH037212A (en) | Dermal preparation for external use | |
JPS58128310A (en) | Skin conditioner | |
JP2000086483A (en) | Skin preparation for external use |